Bone Biologics Corp
Developing a protein-based bone graft for targeted bone regeneration in spinal fusion.
BBLG | NDAQ
Overview
Corporate Details
- ISIN(s):
- US0980703039 (+1 more)
- LEI:
- Country:
- United States of America
- Address:
- 2 BURLINGTON WOODS DRIVE,, 1803 BURLINGTON
- Website:
- https://www.bonebiologics.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of medical and dental instruments and supplies
Description
Bone Biologics Corporation is a clinical-stage medical device and biotechnology company specializing in orthobiologics for bone regeneration. The company is advancing its proprietary recombinant human protein growth factor, NELL-1, a technology developed at UCLA. Its lead product candidate, NB1, is a bone graft substitute combining NELL-1 with a demineralized bone matrix. NB1 is currently in clinical trials for use in spinal fusion procedures. The company's technology aims to provide rapid, targeted, and guided bone regeneration, accelerating healing while forming bone only in specific areas without causing inflammation or unwanted growth.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Bone Biologics Corp filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Bone Biologics Corp
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Bone Biologics Corp via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
